Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNX203
- Development stage
- Preclinical
- Lead developer
- GlycoNex
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GNX203 is a bispecific, glycan-directed antibody-drug conjugate (ADC) being developed by GlycoNex Inc. for the treatment of solid tumors. It is part of GlycoNex's specialized platform that targets tumor-associated glycan antigens, which are specific carbohydrate structures overexpressed on cancer cells. GNX203 is designed to integrate precise glycan recognition with the delivery of a potent cytotoxic payload, aiming to inhibit tumor growth while minimizing off-target side effects. The drug is currently in the lead optimization stage of development and represents an evolution of GlycoNex's ADC technology, which includes other candidates like GNX102 and GNX201.
02
Targets
TAG-1 (Contactin-2)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on GNX203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNX203.